IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
DATE: 30 September 2024 CATEGORY: PRESS RELEASE IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer - Casitas B-lineage lymphoma…